KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Accumulated Expenses (2016 - 2025)

Amgen has reported Accumulated Expenses over the past 17 years, most recently at $18.5 billion for Q4 2025.

  • Quarterly results put Accumulated Expenses at $18.5 billion for Q4 2025, up 5.0% from a year ago — trailing twelve months through Dec 2025 was $18.5 billion (up 5.0% YoY), and the annual figure for FY2025 was $18.5 billion, up 5.0%.
  • Accumulated Expenses for Q4 2025 was $18.5 billion at Amgen, up from $16.8 billion in the prior quarter.
  • Over the last five years, Accumulated Expenses for AMGN hit a ceiling of $18.5 billion in Q4 2025 and a floor of $9.0 billion in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $13.7 billion (2023), compared with a mean of $13.4 billion.
  • Biggest five-year swings in Accumulated Expenses: fell 3.21% in 2021 and later skyrocketed 30.09% in 2023.
  • Amgen's Accumulated Expenses stood at $10.7 billion in 2021, then increased by 16.71% to $12.5 billion in 2022, then increased by 22.64% to $15.4 billion in 2023, then increased by 14.86% to $17.6 billion in 2024, then increased by 5.0% to $18.5 billion in 2025.
  • The last three reported values for Accumulated Expenses were $18.5 billion (Q4 2025), $16.8 billion (Q3 2025), and $15.0 billion (Q2 2025) per Business Quant data.